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Background. The HIV-1 maturation inhibitor, 3-O-(39,39-dimethylsuccinyl) betulinic acid (bevirimat, PA-457) is a promising
drug candidate with 10 nM in vitro antiviral activity against multiple wild-type (WT) and drug-resistant HIV-1 isolates.
Bevirimat has a novel mechanism of action, specifically inhibiting cleavage of spacer peptide 1 (SP1) from the C-terminus of
capsid which results in defective core condensation. Methods and Findings. Oral administration of bevirimat to HIV-1-
infected SCID-hu Thy/Liv mice reduced viral RNA by .2 log10 and protected immature and mature T cells from virus-mediated
depletion. This activity was observed at plasma concentrations that are achievable in humans after oral dosing, and bevirimat
was active up to 3 days after inoculation with both WT HIV-1 and an AZT-resistant HIV-1 clinical isolate. Consistent with its
mechanism of action, bevirimat caused a dose-dependent inhibition of capsid-SP1 cleavage in HIV-1-infected human
thymocytes obtained from these mice. HIV-1 NL4-3 with an alanine-to-valine substitution at the N-terminus of SP1 (SP1/A1V),
which is resistant to bevirimat in vitro, was also resistant to bevirimat treatment in the mice, and SP1/AIV had replication and
thymocyte kinetics similar to that of WT NL4-3 with no evidence of fitness impairment in in vivo competition assays.
Interestingly, protease inhibitor-resistant HIV-1 with impaired capsid-SP1 cleavage was hypersensitive to bevirimat in vitro
with a 50% inhibitory concentration 140 times lower than for WT HIV-1. Conclusions. These results support further clinical
development of this first-in-class maturation inhibitor and confirm the usefulness of the SCID-hu Thy/Liv model for evaluation
of in vivo antiretroviral efficacy, drug resistance, and viral fitness.
Citation: Stoddart CA, Joshi P, Sloan B, Bare JC, Smith PC, et al (2007) Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv
Mice. PLoS ONE 2(11): e1251. doi:10.1371/journal.pone.0001251
INTRODUCTION
There remains an urgent need for more effective antiretrovirals to
treat HIV/AIDS, in particular novel compounds that have activity
against virus resistant to currently approved treatments. Drug
resistance occurs in .50% of patients on antiretroviral therapy
and is the leading cause of treatment failure [1]. The small-
molecule inhibitor, 3-O-(39,39-dimethylsuccinyl) betulinic acid
(bevirimat, formerly known as PA-457 or DSB) is the lead drug
candidate in a recently described class of antiretrovirals termed
maturation inhibitors [2,3]. The drug holds great promise for
specific and potent pharmacologic inhibition of HIV-1 replication.
Here we report that orally administered bevirimat potently
reduces viral load and prevents human T-cell depletion in a small
animal model of HIV-1 infection.
Bevirimat targets a unique point of vulnerability in the HIV-1
life cycle: cleavage of the 14-amino-acid spacer peptide (SP1) from
the capsid (CA) precursor (p25) in Pr55Gag by the viral protease,
which is the final step required for maturation of the capsid and
optimal virion infectivity [4,5]. Recent structural studies indicate
that CA hexamers polymerize to form a lattice within the mature
HIV-1 virion [6], and it has been proposed by Vogt [7] that
proteolytic maturation of Gag proteins prepares the virion for
a new round on infection by destabilization of the virus core. This
process facilitates CA dissociation in the next target cell and
perhaps promotes reverse transcription of the viral genome. The
bevirimat-mediated block in CA processing results in defective
core condensation and the release of immature virus particles
incapable of productive infection [2,3,8,9]. Pharmacologic in-
hibition of CA-SP1 cleavage leading to virus particles with altered
cores is thus analogous to the phenotype of CA point mutants with
suboptimal core stability that are impaired at an early postentry
step prior to reverse transcription [10]. Bevirimat is a triterpenoid
derivative of betulinic acid, a compound with weak anti-HIV-1
activity isolated from Syzigium claviforum,a nh e r bu s e di nt r a d i t i o n a l
Chinese medicine. When modified by the addition of a dimethyl
succinyl moiety at the 39-hydroxy position to yield bevirimat, 3-O-
(39,39-dimethylsuccinyl) betulinic acid, anti-HIV-1 activity was
increased .1,000 fold [11–14]. Bevirimat has potent [50% inhibition
concentration (IC50)o f,10 nM] antiviral activity against multiple
wild-type (WT) and drug-resistant clinical HIV-1 isolates [2].
In confirmation of the mechanism of action of bevirimat, HIV-1
with an alanine-to-valine (A-to-V) substitution at the N-terminus of
SP1 (and thus at the cleavage junction of CA-SP1) is resistant to
bevirimat in vitro [2]. Further work has identified other in vitro
resistance mutations at the C-terminus of CA and the N-terminus
of SP1 [15], while point deletion mutagenesis showed that amino
acids in the N-terminal half of SP1 serve as determinants of
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conferring bevirimat resistance lead to impaired binding of the
compound to Gag in immature HIV-1 virions during particle
assembly [17].
Here we report potent antiviral activity of bevirimat in the
SCID-hu Thy/Liv mouse model of HIV-1 infection, which we
and others have shown to be highly reproducible and predictive
for the evaluation of in vivo antiretroviral efficacy [18–20]. Twice-
daily oral administration of bevirmat to HIV-1-infected SCID-hu
Thy/Liv mice reduced implant viral loads in a dose-dependent
manner, causing reductions of .2 log10 in HIV-1 RNA and
$90% both in implant p24 concentration and in percentage of
Gag-p24
+ thymocytes at 100 mg/kg per day while preserving
immature and mature T-cell populations. Antiviral activity was
observed in the mice at plasma concentrations that are achievable
in humans by oral dosing. HIV-1 with an A-to-V substitution at
the N-terminus of SP1 is resistant to bevirimat treatment in the
mice. In this animal model, the SP1/A1V mutant had viral
replication and thymocyte depletion kinetics similar to WT HIV-1.
At 28 days after inoculation, there was no evidence of reversion to
WT and no detectable fitness impairment in in vivo competition
assays. Our results confirm the usefulness of the SCID-hu Thy/Liv
model for preclinical evaluation of in vivo antiretroviral efficacy,
drug resistance, and viral fitness.
METHODS
Viruses
The following reagent was obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH:
pNL4-3 from Malcolm Martin [21]. Bevirimat-resistant NL4-3
SP1/A1V (also designated as A364V based on the full Gag
sequence) was supplied by Panacos Pharmaceuticals. Stocks of
NL4-3 and SP1/A1V were prepared by transfection of 293T cells
and collection of supernatants on days 2 or 3. The AZT-resistant
(M41L, T215Y) R5X4 clinical HIV-1 isolate JD was kindly
provided by Mike McCune and prepared by cocultivation of
patient peripheral blood mononuclear cells (PBMCs) and
expansion in phytohemagglutinin (PHA)-activated PBMCs. We
introduced the I54V and V82A protease inhibitor resistance
substitutions into the protease gene of HIV-1 NL4-3 by site-
directed mutagenesis to produce NL4-3 PRI54V+V82A. Virus stocks
were titrated by 50% endpoint assay in PHA-activated PBMCs
with p24 detection by ELISA.
SCID-hu Thy/Liv Mice
Human fetal thymus and liver were obtained through services
provided by a nonprofit organization (Advanced Bioscience
Resources) in accordance with federal, state, and local regulations.
Coimplantation of thymus and liver fragments under the kidney
capsule to create SCID-hu Thy/Liv mice and inoculation of the
Thy/Liv implants with HIV-1 was carried out as described
[18,22]. Male C.B-17 SCID (model #CB17SC-M, homozygous,
C.B-Igh-1
b/IcrTac-Prkdc
scid) mice were obtained at 6–8 weeks of
age from Taconic, and cohorts of 50–60 SCID-hu Thy/Liv mice
were implanted with tissues from a single donor. Implants were
inoculated 18 weeks after implantation with 50 ml of stock virus
(500–2,000 50% tissue-culture infectious doses) or RPMI 1640
medium (mock infection) by direct injection. Animal protocols
were approved by the UCSF Institutional Animal Care and Use
Committee. Groups of 5–8 mice each were treated with the N-
methylglucamine di-salt of bevirimat at 10, 30, and 100 mg/kg
per day (dosed as free-acid equivalents in 10% hydroxypropyl-b-
cyclodextrin vehicle) by twice-daily oral gavage of 200 ml per dose.
Implant Collection and Viral Load Quantification
The Thy/Liv implants were collected from euthanized mice, and
single-cell suspensions were prepared by dispersing the implant
through nylon mesh and processed for p24 ELISA, bDNA assay,
and FACS analysis as described [18,19,23].
Flow Cytometry
Implant cells were stained with phycoerythrin cyanine dye CY7-
conjugated anti-CD4 (BD Biosciences), phycoerythrin cyanine
CY5.5-conjugated anti-CD8 (Caltag), allophycocyanin cyanine
CY7-conjugated anti-CD3 (eBiosciences), and phycoerythrin-
conjugated anti-W6/32 (DakoCytomation). Cells were fixed and
permeabilized with 1.2% paraformaldehyde and 0.5% Tween 20,
stained with fluorescein isothiocyanate-conjugated anti-p24 (Beck-
man Coulter), and analyzed on an LSR II (BD Biosciences). After
collecting 100,000 total cell events, percentages of marker-positive
(CD4
+, CD8
+, and CD4
+CD8
+) thymocytes in the implant
samples were determined by first gating on a live lymphoid cell
population identified by forward- and side-scatter characteristics
and then by CD3 expression.
Western Blot Analysis of HIV-1-Infected Human
Thymocytes
The SCID-hu Thy/Liv implants were collected 21 days after
inoculation, disrupted into a single-cell suspension, and cultured in
RPMI 1640 supplemented with 10% fetal bovine serum and
50 ng/ml IL-7 (growth medium) for 2 h. The dispersed Thy/Liv
implant cells were checked for viability, equally distributed in fresh
growth medium, and incubated for an additional 48 h in the
presence of a range of concentrations of bevirimat free acid. The
culture supernatant was collected, and cellular debris was removed
by centrifugation at 1,0006g. Cell-free supernatants were loaded
onto a 30% sucrose cushion, and virions were sedimented at
27,0006g for 2 h. Samples were normalized based on p24 levels,
and the lysed virions were resolved on a 10–20% denaturing
polyacrylamide gel. The separated viral proteins were then
transferred to a polyvinylidene difluoride membrane, and in-
dividual viral proteins were visualized by Western blotting using
anti-HIV-1 Ig (AIDS Reagent Program) and anti-human IgG
peroxidase conjugate (Pierce). The efficiency of p25 cleavage in
the presence of increasing concentrations of bevirimat was
quantified using a molecular imager (BioRad).
To determine the effect of bevirimat on CA maturation of
protease inhibitor-resistant HIV-1, Western blot analysis was
performed on HIV-1 NL4-3 and NL4-3 PRI54V+V82A virions
collected from transfected 293T cells treated with 20 mM
bevirimat as described above using a p24 specific monoclonal
antibody (AIDS Reagent Program).
RT-PCR and Sequencing of CA-SP1 RNA
Total RNA was extracted from frozen thymocyte pellets using
Trizol LS (Invitrogen) and resuspended in nuclease-free water.
The CA-SP1 region of the HIV-1 gag was amplified by RT-PCR
using 10 ml of purified RNA and AmpliTaq Gold (Applied
Biosystems) according to the manufacturer’s instructions. PCR
amplification was limited to 12–14 cycles, the PCR products were
gel purified (Qiagen) and cloned into the pCR4-TOPO TA vector
(Invitrogen), and DNA from randomly picked bacterial colonies
(100–150 colonies per sample) was sequenced in both directions
(Applied Biosystems). Nucleotide sequences of the amplified CA-
SP1 region were aligned to the NL4-3 reference sequence
(GenBank accession #M19921).
Bevirimat in SCID-hu Mice
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Pooled human PBMCs from six donors were thawed, cultured for
2 days RPMI 1640 supplemented with 10% fetal bovine serum, L-
glutamine, and human lymphocyte IL-2, and inoculated in bulk at
a multiplicity of infection of 0.005. Cells were washed, and
100,000 cells in 100 ml ml were added to triplicate wells of round-
bottom 96-well plates. Wells were treated with 100 ml of serial
half-log dilutions of bevirimat free acid or with medium alone, and
supernatants were assayed at day 7 for p24 by ELISA. Parallel
cellular toxicity determinations were performed by incubating
bevirimat-treated uninfected PBMCs with (4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrasodiumbromide (MTT) on day 7. The 50%
inhibitory concentration (IC50) and 50% cytotoxic concentration
(CC50) were calculated using a 4-parameter curve fit (Softmax Pro,
Molecular Devices).
Analysis of Plasma Bevirimat Concentrations
Mouse plasma samples (20 ml) were diluted to 100 ml with 1%
acetic acid (HAc). Aliquots of the dilutions (50 ml) and bevirimat
serial standards spiked in blank mouse samples were protein-
precipitated by adding 200 ml of ice-cold acetonitrile (ACN)
followed by addition of an internal standard, 3-O-(39,39-dimethyl-
succinyl)-dihydrobetulinic acid) (DSD, 100 ng). The supernatants
had the organic solvent concentration reduced by adding 1.5 ml of
0.1% HAc and were then loaded onto preconditioned Bond Elut
C18 cartridges (Varian). The cartridges were washed with 1 ml of
ACN/0.1% HAc (5:95, v/v) to remove any polar impurities and
then eluted with 2 ml of ACN/0.1% HAc (90:10, v/v). The
eluants were dried and reconstituted in 100 ml of ACN/0.1% HAc
(80:20, v/v), then 10 ml injected onto a liquid chromatography-
mass spectrometry system for analysis. Appropriate standard
curves were prepared similarly with mouse plasma over a concen-
tration range of 0.010 to 20 mg/ml. Liquid chromatography-mass
spectrometry was conducted with gradient elution at 0.3 ml/min
and detection performed with a single quadrupole instrument
fitted with electrospray ionization run in the negative ion mode.
Bevirimat was measured at a m/z of 583.5 and the internal
standard, DSD, at 585.5.
Statistical Analysis
Results are expressed as the mean6SEM for each mouse group.
Nonparametric statistical analyses were performed by use of the
Mann-Whitney U test (StatView 5.0, Abacus Concepts). Data for
mice in each group were compared to those for untreated infected
mice, and p-values #0.050 were considered statistically significant.
RESULTS
Bevirimat Potently Inhibits HIV-1 Replication and Prevents
Thymocyte Depletion In Vivo
We first evaluated the activity of bevirimat against the HIV-1
molecular clone NL4-3 in SCID-hu Thy/Liv mice treated with
10, 30, and 100 mg/kg per day by twice-daily oral administration
beginning 1 day before inoculation by direct injection of the Thy/
Liv implants and continuing until implant collection 21 days after
inoculation. Treatment with bevirimat inhibited viral replication
in a dose-dependent manner, reducing implant HIV-1 RNA by
2.1 log10 copies, p24 by 96% (590 pg versus 24 pg per 10
6 cells),
and Gag-p24
+ thymocytes from 7% to ,1% at 100 mg/kg per
day when compared with untreated mice (Figure 1A). Importantly,
bevirimat treatment caused statistically significant protection of the
implants from virus-mediated loss of cellularity at 10 and 30 mg/
kg per day, from depletion of CD4
+CD8
+ (double positive, DP)
thymocytes at 100 mg/kg per day, and from a reduction in CD4/
CD8 ratio at 30 and 100 mg/kg per day (Figure 1B). Treatment
with the 10% hydroxypropyl-b-cyclodextrin vehicle alone had no
effect on either viral load or thymocyte depletion in this model.
Mice Have High Concentrations of Bevirimat in
Plasma 0.5–1 h after Oral Administration
We measured bevirimat concentrations by high-pressure liquid
chromatography-mass spectrometry in plasma from uninfected
SCID-hu Thy/Liv mice from which serial blood samples were
obtained after the final dose (50 mg/kg) following twice-daily
treatment with 100 mg/kg per day of bevirimat for 21 days. Peak
concentrations of 9 mg/ml (15 mM) bevirimat were attained in
plasma 0.5–1 h after oral administration, demonstrating that the N-
methylglucamine di-salt of bevirimat is orally bioavailable and
capable of achieving peak concentrations 1,500 times higher than
the in vitro anti-HIV-1 IC50 of 10 nM at this dosage level (Figure 2).
We collected plasma from mice that had been treated for 21 days
to assess steady-state concentrations of the drug. The peak levels we
observed are consistent with what has been reported for humans
after either a single dose [24,25] or once-daily dosing for 10 days
[26]. Bevirimat is mainly eliminated by glucuronidation in rats and
humans[24,27].Despitetheshorthalf-lifeofabout2 hinthemouse,
Figure 2 shows that mean plasma concentrations of bevirimat were
.2 mg/ml (.3.4 mM) for 6 h after dosing, and these concentrations
are achievable in humans after oral dosing [24–26].
Postexposure Bevirimat Dosing also Potently
Inhibits HIV-1 Replication
Antiviral activity was confirmed in a second SCID-hu mouse study
with NL4-3inwhich initiation ofbevirimat dosing wasdelayed upto
3daysaftervirusinoculationaswellasinathirdstudywiththeAZT-
resistant clinical isolate JD (Figure 3). While there was some loss of
antiviral potency with delayed dosing initiation, viral load reductions
remained .1.0 log10 in all treated groups, including the AZT-
resistant isolate. To confirm the target of action of bevirimat, NL4-3
with an A-to-V substitution at the N-terminal amino acid of SP1,
which has been shown to be resistant to bevirimat in vitro (6), was
tested in the mouse model. As expected, the SP1/A1V mutant was
resistant to bevirimat treatment but fully sensitive to 3TC (Figure 3).
Bevirimat Inhibits p24 Release from the CA
Precursor (p25) in HIV-1-Infected Human
Thymocytes
The CA precursor protein (p25) includes a 14-amino-acid SP1
spacer peptide that separates CA from nucleocapsid. It has been
convincingly shown in vitro that bevirimat inhibits the cleavage of
p25 (CA-SP1) to p24 (CA), leading to a dose-dependent accumu-
lation of p25 in both cell and virion fractions of HIV-1-transfected
HeLa cells [2]. We asked whether this was also true for HIV-1-
infected implant thymocytes collected from SCID-hu Thy/Liv mice
and cultured ex vivo in the presence of bevirimat. Consistent with
earlier data, bevirimat specifically disrupted the maturation of CA in
virus purified from supernatants of HIV-1-infected human thymo-
cytes, leading to an accumulation of p25 in virions in a dose-
dependent manner (Figure 4). Although changes in the levels of
MAp17 and p41 were seen 5 and 20 mM, these doses are 30–100
times higher than the concentration required for impairment of CA-
SP1 cleavage (0.2 mM) and were likely the result of cytotoxicity. The
specificity of bevirimat for CA-SP1 cleavage is also supported by the
lack of any obvious treatment effects on the levels of virion reverse
transcriptase (RTp66) and integrase (INp31) and the lack of
uncleaved NC-SP2-p6 at 15 kDa.
Bevirimat in SCID-hu Mice
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Replication Capacity in the SCID-hu Thy/Liv Mouse
Model
Despite the lack of evidence in Figure 4 and in ref. [2] that
cleavage of the CA precusor (p25) to mature CA is significantly
perturbed in bevirimat-resistant HIV-1 NL4-3 SP1/A1V, it is
possible that this CA-SP1 cleavage site mutation could still affect
replication capacity as a result of more subtle defects in CA
maturation. Indeed, the A-to-V substitution at the N-terminus of
SP1 has been reported to cause a twofold decrease in virus
production in transfected COS-7 and HeLa cells [28], and
Figure 1. Bevirimat Potently Inhibits HIV-1 Replication and Protects Thymocytes from Virus-Mediated Depletion in Vivo. SCID-hu Thy/Liv mice
were treated with bevirimat by twice-daily oral gavage beginning 1 day before inoculation of implants with HIV-1 NL4-3, and dosing was continued
until implant collection 21 days after inoculation. Antiviral efficacy was assessed by determining implant viral load (A) and protection from thymocyte
depletion (B) for bevirimat-treated mice and mice treated with 10% hydroxypropyl-b-cyclodextrin vehicle alone. Mock-infected mice were not
treated. Data are expressed as means6SEM; *p#0.05 for bevirimat- or vehicle-treated mice versus untreated mice by the Mann-Whitney U test.
doi:10.1371/journal.pone.0001251.g001
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SP1 as a possible mechanism for resistance of SP1/A1V in an in
vitro particle assembly system. In this assay, the Gag protein forms
immature particle structures, although additional mutations at the
cleavage site and within SP1 suggested that resistance does not
strictly correlate with the rate of cleavage. The more rapid
processing of CA-SP1 in the SP1/A1V mutant was confirmed in
pulse-chase experiments by Adamson et al. [15], who also showed
the extent of CA-SP1 processing does not correlate with bevirimat
resistance.
To determine whether bevirimat resistance might confer
a fitness disadvantage to the virus in the SCID-hu Thy/Liv
mouse model, we compared the replication capacity of SP1/A1V
to WT NL4-3 in mice at weekly intervals after inoculation and
found no evidence for impaired replication capacity of the SP1/
A1V mutant (Figure 5). For both viruses, peak viral loads were
attained 21–28 days after inoculation as the implants became
severely depleted of thymocytes. We obtained similar time-
dependent increases in viral RNA and p24 for both viruses with
no statistically significant differences in viral load at any of the
three time points (Figure 5A). The results were mirrored by similar
thymocyte depletion kinetics in terms of reductions in implant
cellularity, thymocyte viability, percentage of DP thymocytes, and
CD4/CD8 ratio (Figure 5B). Comparison of NL4-3 and SP1/A1V
kinetics by area-under-the curve analysis showed SP1/A1V to have
90%the area-under-the curve of NL4-3for viral RNA,74%forp24,
and 79–99.9% for the parameters of thymocyte depletion shown in
Figure 5B. Further support for the lack of impaired replication
capacityoftheSP1/A1Vmutantwasprovided byviruscompetitions
performed by coinfecting Thy/Liv implants with a mixture of
equivalent infectious units (500 50% tissue-culture infectious doses
each) of WT NL4-3 and SP1/A1V and collecting them 21 or 28
days after coinoculation. As shown in Figure 6 and Table 1, both
genomes were detected in six of nine coinfected mice by sequencing
CA after RNA RT-PCR amplification. In mixing experiments, one
genome had to be present at 10–20% of the total for the minor
species to be detected as a peak (the A-to-V substitution in SP1 is
conferred by a C-to-T mutation at nucleotide 1880) in the
sequencing chromatogram. We surmised that the three coinfected
sampleswith onlytheA1Vgenomeseeninthechromatogrammight
have WT genome below the level of detection, so we performed
colony sequencing to obtain more precise percentages. The clonal
analysisshowed 8–23% A1V sequences for thesethree implants,and
the percentages for the other implants were in agreement with the
relative proportions of the genomes in the chromatograms. For all
nine mice, there was a mean of 44% WT and 56% A1V clones. In
addition, there was no evidence of reversion to the WT alanine in
SP1/A1V-infected implants at day 28.
Protease Inhibitor-Resistant HIV-1 Is Hypersensitive
to Bevirimat
HIV-1 with drug-resistance substitutions in protease display
multiple Pr55Gag cleavage defects, in particular at the CA-SP1
junction, resulting from impairment of the catalytic efficiency of
the mutant enzyme [30,31]. We reasoned that this might synergize
with bevirimat activity, so we treated WT- and protease-mutant
(PRI54V+V82A)-transfected 293T cells with bevirimat, and subjected
supernatant virions to Western blot analysis of p25 cleavage. As
expected, the CA precursor (p25) of NL4-3 PRI54V+V82A was
incompletely cleaved (64% cleavage) whereas the p25 of WT NL4-
3 was cleaved to completion (Figure 7A). Interestingly, p25
cleavage of NL4-3 PRI54V+V82A was even more impaired in the
presence of 20 mM bevirimat (29% cleavage). We anticipated that
Figure 2. Mice have High Concentrations of Bevirimat in Plasma 0.5–
1 h after Oral Administration. Serial plasma samples were collected
after the final dose from SCID-hu Thy/Liv mice that had been treated
with 100 mg/kg per day for 21 days. Mean6SEM for four mice.
doi:10.1371/journal.pone.0001251.g002
Figure 3. Postexposure Dosing of Bevirimat also Reduces Viral Load.
Mice were treated by twice-daily oral gavage with bevirimat at 100 mg/
kg per day beginning 1 day before (21), 1 day after (+1), or 3 days after
(+3) virus inoculation of Thy/Liv implants with HIV-1 NL4-3 and JD.
Dosing was continued until implant collection 14 days (JD) and 21 days
(NL4-3) after inoculation. Antiviral efficacy was assessed by determining
cell-associated HIV-1 RNA and p24. There was no reduction in viral load
in bevirimat-treated mice inoculated with bevirimat-resistant SP1/A1V,
whereas 3TC treatment (30 mg/kg per day by twice-daily oral gavage)
was highly effective. Data are expressed as means6SEM; *p#0.05 for
treated mice versus untreated mice by the Mann-Whitney U test for 6–8
mice per group.
doi:10.1371/journal.pone.0001251.g003
Bevirimat in SCID-hu Mice
PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1251this might render NL4-3 PRI54V+V82A hypersensitive to bevirimat
compared to WT NL4-3, and this was shown to be the case in
PHA-activated PBMCs (Figure 8). The mean IC50 for NL4-3
PRI54V+V82A was 0.01060.0032 nM (n=7; range: 0.0031–0.024),
which was 140 times lower than for WT NL4-3 (1.460.47 nM;
range: 0.18–3.0).
DISCUSSION
In this study we demonstrate that the HIV-1 maturation inhibitor
bevirimat has potent antiviral activity in SCID-hu Thy/Liv mice
after oral administration. This is the first report demonstrating in
vivo activity of bevirimat and the first time in a number of years
that a novel target for HIV-1 inhibition has been identified and
validated in an animal model. In HIV-1-infected humans treated
with 10 days of oral bevirimat monotherapy, potent suppression of
viral replication was observed with a median 1 log10 reduction in
viral load at the 200-mg dose level (unpublished data). When an
adjustment is made for the 12-fold difference in surface area-to-
body weight ratio between mice and humans [32,33], the human
dose of 200 mg per day corresponds to 41 mg/kg per day in the
mouse. This approximates the 100 mg/kg per day dosage level
that we show here to have potent antiviral activity in the SCID-hu
Thy/Liv model.
This analysis also confirmed the target specificity of the drug
which did not affect the processing of Pr55Gag except at the CA-
SP1 junction in infected human thymocytes treated ex vivo.
Additionally, bevirimat treatment had no effect on the processing
of CA-SP1 in bevirimat-resistant SP1/A1V, as no uncleaved CA
precursor (p25) was detected even at a concentration of 20 mM.
These results confirm the antiviral mechanism of action of
bevirimat and are consistent with the potent inhibition of HIV-1
replication we have observed in the SCID-hu Thy/Liv model.
While the SP1/A1V mutant was shown to be replication
competent in this model, it should be noted that the amino acid
sequence at the CA-SP1 cleavage junction, including the alanine
at position one of SP1, is highly conserved among different HIV-1
strains and to our knowledge no naturally occurring polymorph-
isms have been reported at this residue. This suggests that there
may be selective pressure to maintain this sequence in HIV-1-
infected humans, and de novo generation of the SP1/A1V mutant
may not readily occur. Further support for this assertion is
provided by the lack of resistance development observed in viral
population sequencing of clinical samples from patients treated
with bevirimat in a 10-day monotherapy study (unpublished
observations) where there was continued drug exposure for
approximately three weeks as a result of bevirimat’s long half-life
of 2.5–3 days [26]. Nevertheless, the fact that the SP1/A1V
mutant is replication competent in this model does suggest that
continued screening for this mutation in the clinical program is
warranted. Single mutations in reverse transcriptase (RT) confer
resistance to nucleoside RT inhibitors (M184V, K65R) and
nonnucleoside RT inhibitors (Y181C) without significantly
compromising viral fitness, yet these drugs are used in most
antiretroviral regimens. The standard of care for drug-naı ¨ve
Figure 4. Bevirimat Inhibits p24 Release from the Capsid p25 Precursor in Human Thymocytes. Thymocytes dispersed from NL4-3- and SP1/A1V-
infected SCID-hu Thy/Liv implants were cultured in the presence of the indicated range of concentrations of bevirimat for 2 days. Purified virions was
lysed and individual viral proteins were detected with HIV-1 Ig. Note the target-specific and dose-dependent reduction of CAp25 cleavage in the
presence of bevirimat. The presence of the drug does not affect the stoichiometry of the precursor Pr55Gag polyprotein nor does it inhibit cleavage
of the matrix protein, MAp17 (lower panel, longer exposure).
doi:10.1371/journal.pone.0001251.g004
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the specific potency of any of the drugs in the combination.
Our observation that protease-inhibitor resistant NL4-3
PRI54V+V82A with impaired CA-SP1 cleavage is hypersensitive to
bevirimat activity represents a unique form of antiviral synergy in
which a drug-resistant enzyme inefficiently cleaves the same site
where a drug exerts its antiviral activity. This observation has
important clinical relevance because it might be predicted that
patients with protease-inhibitor resistance mutations that impair
CA-SP1 cleavage (such as PRI54V+V82A) might respond to
bevirimat treatment with greater viral load reductions than
drug-naı ¨ve patients with WT HIV-1. It is not feasible to study
protease-inhibitor-resistant HIV-1 in the SCID-hu Thy/Liv model
because replication rates of the resistant mutants are not
comparable to the rates in other systems [20]. Replication of
HIV-1 PRI54V+V82A occurs reproducibly in PHA-activated
PBMCs, so in vitro antiviral assays were performed with these cells.
The SCID-hu Thy/Liv studies presented here showed potent
suppression of HIV-1 replication by bevirimat whether it was
administered before or up to three days after inoculation, and
Figure 5. The A1V Mutation in SP1 Does Not Affect Kinetics of Viral Replication or Thymocyte Depletion. Bevirimat-resistant SP1/A1V replicates
and depletes thymocytes with kinetics comparable to wild-type NL4-3 in SCID-hu Thy/Liv mice. Viral replication was assessed by determining implant
viral load (A), and thymocyte depletion was assessed by total implant cellularity, thymocyte viability, and CD4/CD8 ratio (B) for NL4-3-infected versus
SP1/AIV-infected mice for 6 mice per group. Data are expressed as means6SEM; there were no statistically significant differences in viral load or
thymocyte depletion at any of the three time points. The number in each graph is the proportion of SP1/A1V to NL4-3 in area under the curve.
doi:10.1371/journal.pone.0001251.g005
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clinical isolate. Because drug resistance, and particularly cross-
resistance, is a significant problem in antiretroviral therapy, it is
notable that we were able to demonstrate that 3TC was highly
effective against bevirimat-resistant SP1/A1V.
The efficacy of bevirimat observed in SCID-hu Thy/Liv mice
clearly establishes the proof-of-concept for this novel inhibitor of
HIV-1 replication. Currently, all approved small molecule, orally
bioavailable inhibitors of HIV-1 replication target one of two HIV-1
viral enzymes: reverse transcriptase or protease. Small-molecule
antiretroviral drugs in development include agents targeting the
HIV-1integraseenzymeortheviralcoreceptors,CCR5orCXCR4.
In contrast, bevirimat is a small orally bioavailable molecule that
does not inhibit HIV-1 replication through a viral enzyme or
receptor, thus providing a uniquely high target specificity with the
potential for minimal adverse affects on cellular pathways.
Taken together, these results establish bevirimat as a potent
inhibitor of HIV replication in vivo and confirm the success of the
SCID-hu Thy/Liv model as a valuable predictor of clinical utility.
In short-term (i.e., 10-day) human studies, bevirimat was well
tolerated and had pharmacokinetics supporting once daily or even
less frequent oral dosing [24–26]. These results support further
clinical development of this first-in-class maturation inhibitor and
demonstrate the usefulness of the SCID-hu Thy/Liv model for
evaluating in vivo antiretroviral efficacy, drug resistance, and viral
fitness, particularly for novel targets of antiviral inhibition.
Figure 6. In Vivo Competitions Reveal No Impairment of SP1/A1V Replication. Sequencing of CA-SP1 RNA from three SCID-hu Thy/Liv mice
coinfected with equivalent infectious units of NL4-3 and SP1/A1V reveal no impairment of SP1/A1V replication 28 days after implant inoculation. The
A-to-V substitution in SP1 is conferred by a C-to-T mutation at nucleotide 1880.
doi:10.1371/journal.pone.0001251.g006
Table 1. In Vivo Competition Results for NL4-3 and Bevirimat-Resistant SP1/A1V.
..................................................................................................................................................
Mouse no. p24 (pg per 10
6 cells)
HIV-1 RNA (log
10
copies per 10
6 cells)
Sequences detected in
chromatogram (predominant)
a Colony sequences (%)
NL4-3 A1V
Expt 1 (28 days)
37 2,856 6.89 Both (NL4-3) 63 37
38 1,212 6.66 Both (A1V) 49 51
41 1,227 6.53 A1V 7 93
Expt 2 (21 days)
32 329 5.60 Both (NL4-3) 45 55
33 529 5.81 Both (NL4-3) 70 30
34 201 5.35 A1V 8 92
35 420 5.84 A1V 23 77
36 210 5.12 Both (NL4-3) 67 33
40 215 5.71 Both (NL4-3) 61 39
MEAN (9 mice) 44 56
aViral species identified by sequencing amplicons generated after RT-PCR of CA RNA as shown in Figure 6.
doi:10.1371/journal.pone.0001251.t001
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